Azaliya D. Valitova

Azaliya D. Valitova

Auto-generated profile, based on publicly available information

Azaliya D. Valitova

National Medical Research Center for Hematology

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2023 in Kazan medical journal
Verified
Journal Article
Closed access
PDF file
AVAzaliya D. Valitova
Azaliya D. Valitova
ZKZulfinaz M. Kadyrova
Zulfinaz M. Kadyrova
VOVladimir N. Oslopov
Vladimir N. Oslopov
YOYulia V. Oslopova
Yulia V. Oslopova
EKElena V. Khazova
Elena V. Khazova
Anemia of chronic disease occurs in patients with infectious, autoimmune, kidney diseases, neoplasia, inflammatory bowel disease, obesity, diabetes mellitus, congestive heart failure, and chronic lung disease. This variant of anemia is characterized primarily by impaired iron homeostasis, the suppressive effect of pro-inflammatory cytokines on erythropoiesis, and changes in the erythrocyte membrane that worsen their survival. Anemia of chronic disease is micro- or normocytic anemia with low levels of reticulocytes. In anemia of chronic disease, serum iron and transferrin levels are usually reduced or normal, and serum ferritin levels are within reference values or elevated. The article provides a review of studies on epidemiology, including age aspects, provides information on the etiology and prognosis in patients with anemia of chronic diseases. The issues of the history of anemia of chronic diseases and its place in the structure of all anemias are also covered. Anemia of inflammation is recognized as a widespread pathology; it occupies 40% in the structure of all anemias. It is important to note that anemia of chronic diseases, while accompanying a number of dangerous diseases, actually serves as a natural defense mechanism. This is due to the occurrence of iron starvation for microorganisms, since inflammatory reactions increase the synthesis of iron proteins, which quickly extract extracellular and unbound iron. This mechanism allows a person to destroy the infection in time with the help of innate immunity. The article reveals the pathogenetic aspects of anemia of inflammation development and data on the role of iron in the functioning of macro- and microorganisms. Particular attention is paid to the differential diagnosis of anemia of chronic diseases and iron deficiency anemia, key diagnostic hematological markers of anemia, iron metabolism, inflammation and erythropoiesis are given. The pros and cons of therapy options, as well as possible new pathogenetic methods for the treatment of anemia of chronic diseases, are described.

7 April 2026 in Russian journal of hematology and transfusiology
Verified
Journal Article
Closed access
AGA. E. Grachev
A. E. Grachev
ESE. A. Shatokhina
E. A. Shatokhina
AVA. D. Valitova
A. D. Valitova
DCD. B. Churkina
D. B. Churkina
Anastasiia A. ShumilovaAnastasiia A. Shumilova
Anastasiia A. Shumilova
EGE. O. Gribanova
E. O. Gribanova
Introduction. Monoclonal gammapathy is a heterogeneous group of diseases associated with the formation of a clone of plasma cells in the bone marrow and the secretion of paraprotein. Aim: to present clinical observations demonstrating the effectiveness of therapy in patients with scleromyxedema associated with monoclonal gammapathy. Main findings. Scleromyxedema is one of the dermatological manifestations of monoclonal gammapathy. It is characterized by thickening of the skin due to excessive formation and deposition of mucin in the dermis, involvement of internal organs in the process. Without therapy, this condition can cause complications from the gastrointestinal tract, respiratory, cardiovascular and nervous systems. An effective treatment method is clone-reducing therapy using proteasome inhibitors, antitumor immunomodulators, alkylating drugs, glucocorticoids, as well as subsequent melphalan chemotherapy, and autologous hematopoietic table cell transplantation. As a result of the treatment, regression of dermatological manifestations and complete reduction of the clone of plasma cells were achieved.